Consolidated Balance Sheets (USD $) In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Current assets:
Cash and cash equivalents	$ 370,741	$ 376,727
Accounts receivable, net of allowances of approximately $47.0 million and $28.6 million at December 31, 2014 and 2013	155,691	101,587
Inventory	81,450	87,105
Deferred tax assets	33,080	13,431
Prepaid expenses and other current assets	16,012	12,591
Total current assets	656,974	591,441
Fixed assets, net	40,060	39,268
Intangible assets, net	892,659	836,273
Goodwill	286,532	257,694
Restricted cash	1,446	1,574
Other assets	8,034	15,032
Total assets	1,885,705	1,741,282
Current liabilities:
Accounts payable	19,799	26,911
Accrued expenses	159,252	142,290
Current portion of contingent purchase price	210,422	0
Deferred revenue	14,350	5,052
Total current liabilities	403,823	174,253
Contingent purchase price	140,712	302,363
Convertible senior notes (due 2017)	246,676	236,088
Deferred tax liability	164,459	128,677
Other liabilities	9,944	7,740
Total liabilities	965,614	849,121
Stockholders’ equity:
Preferred stock, $1.00 par value per share, 5,000,000 shares authorized; no shares issued and outstanding	0	0
Common stock, $.001 par value per share, 125,000,000 shares authorized; 67,667,468 issued and 65,474,486 outstanding at December 31, 2014 and 66,590,875 issued and 64,397,893 outstanding at December 31, 2013	68	66
Additional paid-in capital	1,045,078	991,982
Treasury stock, at cost; 2,192,982 at December 31, 2014 and December 31, 2013	(50,000)	(50,000)
Accumulated deficit	(77,109)	(44,899)
Accumulated other comprehensive income (loss)	2,528	(4,652)
Total The Medicines Company stockholders’ equity	920,565	892,497
Non-controlling interest in joint venture	(474)	(336)
Total stockholders’ equity	920,091	892,161
Total liabilities and stockholders’ equity	$ 1,885,705	$ 1,741,282